ArticlePolymers2022
Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity.
Article in Polymers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Micelle-Based Ocular Inserts for Sustained Delivery and Improved Corneal Permeation of Rebamipide in Dry Eye Disease.Pharmaceutics · 2026Article
- Self-Assembly and Gelation Behavior of Methacrylated PEO-PPO-PEO Triblock Copolymer Pluronic F127.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Emerging Treatment Options of Pluronic in Designing Colloidal Nano and Micro Carriers for Various Therapies.Recent patents on nanotechnology · 2025Review
- Colloidal Structure Dictates Antimicrobial Efficacy in LL-37 Self-Assemblies With Glycerol Monooleate.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Optimizing lipopeptide bioactivity: The impact of non-ionic surfactant dressing.Journal of pharmaceutical analysis · 2024Article
- Embedded 3D Printing for Microchannel Fabrication in Epoxy-Based Microfluidic Devices.Polymers · 2024Article
- Nanomedicines as a cutting-edge solution to combat antimicrobial resistance.RSC advances · 2024Review
- Polymeric Mixed Micelle-Loaded Hydrogel for the Ocular Delivery of Fexofenadine for Treating Allergic Conjunctivitis.Polymers · 2024Article
- Super-Antioxidant Vitamin A Derivatives with Improved Stability and Efficacy Using Skin-Permeable Chitosan Nanocapsules.Antioxidants (Basel, Switzerland) · 2023Article
- Preparation and Primary Bioactivity Evaluation of Novel Water-Soluble Curcumin-Loaded Polymeric Micelles Fabricated with Chitooligosaccharides and Pluronic F-68.Pharmaceutics · 2023Article
- Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy.Pharmaceutics · 2023Review
- Article
- Temperature-Responsive Hydrogel for Silver Sulfadiazine Drug Delivery: Optimized Design and In Vitro/In Vivo Evaluation.Gels (Basel, Switzerland) · 2023Article
- Development of pH-ResponsiveMolecules (Basel, Switzerland) · 2023Article
- Temperature Induced Gelation and Antimicrobial Properties of Pluronic F127 Based Systems.Polymers · 2023Article
- Formulation of Nanomicelles Loaded with Cannabidiol as a Platform for Neuroprotective Therapy.Pharmaceutics · 2022Article
- Direct and Reverse Pluronic Micelles: Design and Characterization of Promising Drug Delivery Nanosystems.Pharmaceutics · 2022Review
- Amphiphilic Block Copolymers: Their Structures, and Self-Assembly to Polymeric Micelles and Polymersomes as Drug Delivery Vehicles.Polymers · 2022Review
- Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic.Polymers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Bacterial oral diseases are chronic, and, therefore, require appropriate treatment, which involves various forms of administration and dosing of the drug. However, multimicrobial resistance is an increasing issue, which affects the global health system. In the present study, a commercial amphiphilic copolymer, Pluronic F127, was used for the encapsulation of 1-(5'-nitrobenzimidazole-2'-yl-sulphonyl-acetyl)-4-aryl-thiosemicarbazide, which is an original active pharmaceutical ingredient (API) previously synthesized and characterized by our group, at different copolymer/API weight ratios. The obtained micellar systems, with sizes around 20 nm, were stable during 30 days of storage at 4 °C, without a major increase of the Z-average sizes. As expected, the drug encapsulation and loading efficiencies varied with the copolymer/API ratio, the highest values of 84.8 and 11.1%, respectively being determined for the F127/API = 10/1 ratio. Moreover, in vitro biological tests have demonstrated that the obtained polymeric micelles (PMs) are both hemocompatible and cytocompatible. Furthermore, enhanced inhibition zones of 36 and 20 mm were observed for the sample F127/API = 2/1 against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.